Ivan Ferkolj - Concepedia

Author

Ivan Ferkolj

Ljubljana University Medical Centre

Also Known As

Ferkolj, I, Ferkolj, Ivan, I Ferkolj, Ivan Ferkolj

Publications

597

Citations

H-Index

Concepts

All Affiliations

Ljubljana University Medical Centre University Clinical Centre Maribor University of Maribor University of Ljubljana University Medical Center Groningen

About

Ivan Ferkolj is an author at Ljubljana University Medical Centre specializing in immunology, medicine, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	284
2	Gastroenterology	5	5	284
3	Immunology	5	5	284
4	Pathology	5	5	284
5	Health Sciences	1	1	178

Ivan Ferkolj

Publications

555

Citations

H-Index

Page 1

	Year	Citations
Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis Uroš Potočnik, Ivan Ferkolj, Damjan Glavač, Genes and Immunity Disease SusceptibilityHealth SciencesMedicineImmunologyGastroenterology	2004	178
Genetic Polymorphism in <i>ATG16L1</i> Gene Influences the Response to Adalimumab in Crohn’s Disease Patients Silvo Koder, Katja Repnik, Ivan Ferkolj, Pharmacogenomics	2015	63
Diagnosing cytomegalovirus in patients with inflammatory bowel disease—by immunohistochemistry or polymerase chain reaction? Nina Zidar, Ivan Ferkolj, Katja Tepeš, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin Polymerase Chain ReactionMolecular Diagnostic TechniquesImmunodeficienciesImmunologyGastroenterology	2015	51
Success and safety of high infliximab trough levels in inflammatory bowel disease David Drobne, Tina Kurent, Saša Golob, Scandinavian Journal of Gastroenterology	2018	46
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease David Drobne, Tina Kurent, Saša Golob, Alimentary Pharmacology & Therapeutics	2019	40
Acute biliary pancreatitis: detection of common bile duct stones with endoscopic ultrasound Borut Štabuc, David Drobne, Ivan Ferkolj, European Journal of Gastroenterology & Hepatology	2008	32
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease Jurij Hanžel, Nejc Sever, Ivan Ferkolj, United European Gastroenterology Journal	2019	27
A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of <i>ATG5</i> , <i>NFKB1,</i> and <i>CRP</i> Genes to Pharmacodynamic Variability Matjaž Deželak, Katja Repnik, Silvo Koder, OMICS A Journal of Integrative Biology	2016	26
How to improve the safety of biologic therapy in Crohn's disease. Ivan Ferkolj PubMed ImmunologyGastroenterologyPathologyBiological TherapyBiologic Therapy	2009	25
Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients Katja Repnik, Silvo Koder, Pavel Skok, Biochemical Genetics Hfe GenePredictive MarkersImmunologyGastroenterologyPathology	2016	17

Page 1